<clinical_study>
<study_id>
<org_name>
AstraZeneca 
</org_name>
<org_full_name>
 AstraZeneca 
</org_full_name>
<org_study_id>
  2993-114
</org_study_id>
<nct_id>
  NCT00097500
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
 AstraZeneca 
</agency>
</lead_sponsor>
<sponsor>
<agency>
  Eli Lilly and Company
</agency>
</sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<regulatory_authority>
  Finland: Finnish Medicines Agency
</regulatory_authority>
<regulatory_authority>
  Netherlands: Medicines Evaluation Board (MEB)
</regulatory_authority>
<regulatory_authority>
  Sweden: Medical Products Agency
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus&#174; injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2014-06 
</date>
</status_block>
<start_date>
<date>
  2004-09
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2009-12
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2009-12
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Beta-cell Function After 52 Weeks of Therapy
</measure>
<time_frame>
  Baseline (week -2) and 52 weeks
</time_frame>
<description>
<textblock>
  Treatment effect on beta-cell function as measured by the ratio of Week 52 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period [i.e., clamp time 290 min to 300 min]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 52 divided by arginine-stimulated insulin secretion at baseline [week -2]).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Beta-cell Function 4 Weeks After Cessation of Therapy
</measure>
<time_frame>
  Baseline (week -2) and 56 weeks
</time_frame>
<description>
<textblock>
  Treatment effect on beta-cell function as measured by the ratio of Week 56 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period [i.e., clamp time 290 min to 300 min]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 56 divided by arginine-stimulated insulin secretion at baseline [week -2]).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Change in First Phase C-peptide Release
</measure>
<time_frame>
  baseline (week -2), 52 weeks, and 56 weeks
</time_frame>
<description>
<textblock>
  Ratio of first phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to first phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline [week -2]).  C-peptide is measured as a surrogate marker of insulin secretion.  First phase C-peptide/insulin release is measured during the first ten minutes of glucose infusion during a hyperglycemic clamp procedure.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Change in Second Phase C-peptide Release
</measure>
<time_frame>
  baseline (-2 weeks), 52 weeks, and 56 weeks
</time_frame>
<description>
<textblock>
  Ratio of second phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to second phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline [week -2]).  C-peptide is measured as a surrogate marker of insulin secretion.  Second phase C-peptide/insulin release is measured from time=10 minutes to time=80 minutes of glucose infusion during a hyperglycemic clamp procedure.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Change in Glycosylated Hemoglobin (HbA1c)
</measure>
<time_frame>
  Week 0 and week 52
</time_frame>
<description>
<textblock>
  Change in HbA1c from week 0 to week 52 (i.e., HbA1c at week 52 minus HbA1c at week 0).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Change in Fasting Plasma Glucose
</measure>
<time_frame>
  0 weeks and 52 weeks
</time_frame>
<description>
<textblock>
  Change in fasting plasma glucose from week 0 to week 52 (i.e., fasting plasma glucose at week 52 minus fasting plasma glucose at week 0).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Seven Point Self Monitored Blood Glucose (SMBG) Measurements
</measure>
<time_frame>
  0 weeks and 52 weeks
</time_frame>
<description>
<textblock>
  SMBG measured at 7 time points (before and after breakfast, before and after lunch, before and after dinner, at bedtime).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Change in Body Weight
</measure>
<time_frame>
  0 weeks and 52 weeks
</time_frame>
<description>
<textblock>
  Change in body weight from week 0 to week 52 (i.e., body weight at week 52 minus body weight at week 0).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  M-value at Baseline, Week 52 and Week 56
</measure>
<time_frame>
  baseline (week -2), 52 weeks, and 56 weeks
</time_frame>
<description>
<textblock>
  M-value at baseline (week -2), week 52 (end of on-drug period), and week 56 (during off-drug period).  Insulin sensitivity was assessed during the euglycemic/hyperglycemic clamp test at baseline (week -2), week 52, and week 56.  Insulin-mediated glucose uptake (M-value) was calculated as the mean glucose requirement during the 90-120 minute interval of the clamp.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  69
</enrollment>
<condition>
  Type 2 Diabetes Mellitus
</condition>
<arm_group>
<arm_group_label>
  Exenatide Arm
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Exenatide and Metformin
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  Insulin Glargine Arm
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
  Insulin Glargine and Metformin
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  exenatide
</primary_name>
<description>
<textblock>
  subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
</textblock>
</description>
<arm_group_label>
  Exenatide Arm
</arm_group_label>
<other_name>
  Byetta
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Insulin glargine
</primary_name>
<description>
<textblock>
  subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
</textblock>
</description>
<arm_group_label>
  Insulin Glargine Arm
</arm_group_label>
<other_name>
  Lantus
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Metformin
</primary_name>
<description>
<textblock>
  Patients usual dosage
</textblock>
</description>
<arm_group_label>
  Exenatide Arm
</arm_group_label>
<arm_group_label>
  Insulin Glargine Arm
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - Diagnosis of type 2 diabetes, but otherwise healthy
    - HbA1c between 6.6% and 9.5%, inclusive.
    - Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.
    - Treated with a stable dose of metformin for at least 2 months prior to screening.  
 
  Exclusion Criteria:
    - Patients previously in a study using exenatide.
    - Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening).
    - Treated with insulin within 3 months of screening.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
  75 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Vice President, Research and Development, MD
</name>
<affiliation>
<agency>
  Amylin Pharmaceuticals
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Helsinki
</city>
<state>
</state>
<zip>
</zip>
<country>
  Finland
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Amsterdam
</city>
<state>
</state>
<zip>
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Goteborg
</city>
<state>
</state>
<zip>
</zip>
<country>
  Sweden
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<keyword>
  diabetes
</keyword>
<keyword>
  exenatide
</keyword>
<keyword>
  exendin-4
</keyword>
<keyword>
  Amylin
</keyword>
<keyword>
  Lilly
</keyword>
<initial_release_date>
  2004-11-24
</initial_release_date>
<last_release_date>
2014-06-04 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2010-12-24
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  7.8
</dispersionspread>
<parametervalue>
  58.4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  8.4
</dispersionspread>
<parametervalue>
  58.4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  7.3
</dispersionspread>
<parametervalue>
  58.3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Mean
</parametertype>
<title>
Age, Continuous  
</title>
<unitofmeasure>
  years
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  24
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  13
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  11
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  45
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  23
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  22
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  3.84
</dispersionspread>
<parametervalue>
  30.52
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  4.15
</dispersionspread>
<parametervalue>
  30.87
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  3.49
</dispersionspread>
<parametervalue>
  30.13
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
Study  Specific  Measure 
</title>
<unitofmeasure>
  kg/m^2
</unitofmeasure>
<othertitle>
  Body Mass Index (BMI)
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  13.03
</dispersionspread>
<parametervalue>
  91.44
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  12.66
</dispersionspread>
<parametervalue>
  90.56
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  13.56
</dispersionspread>
<parametervalue>
  92.39
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
Study  Specific  Measure 
</title>
<unitofmeasure>
  kg
</unitofmeasure>
<othertitle>
  Body weight
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  0.85
</dispersionspread>
<parametervalue>
  7.50
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  0.89
</dispersionspread>
<parametervalue>
  7.58
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  0.81
</dispersionspread>
<parametervalue>
  7.41
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
Study  Specific  Measure 
</title>
<unitofmeasure>
  percentage
</unitofmeasure>
<othertitle>
  Glycosylated hemoglobin (HbA1c)
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  4.28
</dispersionspread>
<parametervalue>
  4.88
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  4.70
</dispersionspread>
<parametervalue>
  5.72
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  3.62
</dispersionspread>
<parametervalue>
  3.97
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
Study  Specific  Measure 
</title>
<unitofmeasure>
  years
</unitofmeasure>
<othertitle>
  Duration of diabetes
</othertitle>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  36
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
</baselinereportinggroup>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  33
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<subjectsanalyzed>
  69
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  GT60
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
2014-06-04T10:28:00-04:00 
</lastupdatetimestamp>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.27
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2.89
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.11
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.15
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Treatment effect on beta-cell function as measured by the ratio of Week 52 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period [i.e., clamp time 290 min to 300 min]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 52 divided by arginine-stimulated insulin secretion at baseline [week -2]).
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  Baseline (week -2) and 52 weeks
</timeframe>
<title>
  Beta-cell Function After 52 Weeks of Therapy
</title>
<unitofmeasure>
  ratio
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.0001
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Evaluable population
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.06
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.02
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.07
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.08
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Treatment effect on beta-cell function as measured by the ratio of Week 56 arginine-stimulated insulin secretion during a hyperglycemic clamp(specifically, the incremental AUC of insulin with respect to basal value over a 10 min period [i.e., clamp time 290 min to 300 min]) to that at baseline (i.e., the ratio is calculated as arginine-stimulated insulin secretion at week 56 divided by arginine-stimulated insulin secretion at baseline [week -2]).
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  Baseline (week -2) and 56 weeks
</timeframe>
<title>
  Beta-cell Function 4 Weeks After Cessation of Therapy
</title>
<unitofmeasure>
  ratio
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.4185
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Evaluable population
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.11
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.72
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.07
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.13
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  52 weeks
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.05
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0.95
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.06
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.06
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  56 weeks
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Ratio of first phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to first phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline [week -2]).  C-peptide is measured as a surrogate marker of insulin secretion.  First phase C-peptide/insulin release is measured during the first ten minutes of glucose infusion during a hyperglycemic clamp procedure.
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  baseline (week -2), 52 weeks, and 56 weeks
</timeframe>
<title>
  Change in First Phase C-peptide Release
</title>
<unitofmeasure>
  ratio
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  Statistical analysis at week 52.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  &lt;0.0001
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  Statistical analysis at week 56.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.1188
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  29
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Evaluable population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.18
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2.88
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.07
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.01
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  52 weeks
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.05
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.00
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.06
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  1.08
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  56 weeks
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Ratio of second phase C-peptide response to glucose at 52 weeks (end of on-drug period) and 56 weeks (during off-drug period) compared to second phase C-peptide response to glucose at baseline (i.e., C-peptide response to glucose at week 52 or week 56 divided by C-peptide response to glucose at baseline [week -2]).  C-peptide is measured as a surrogate marker of insulin secretion.  Second phase C-peptide/insulin release is measured from time=10 minutes to time=80 minutes of glucose infusion during a hyperglycemic clamp procedure.
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  baseline (-2 weeks), 52 weeks, and 56 weeks
</timeframe>
<title>
  Change in Second Phase C-peptide Release
</title>
<unitofmeasure>
  ratio
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  Statistical analysis at week 52.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  &lt;0.0001
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  Statistical analysis at week 56.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.1996
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Evaluable population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.14
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -0.97
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.15
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -0.87
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Change in HbA1c from week 0 to week 52 (i.e., HbA1c at week 52 minus HbA1c at week 0).
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  Week 0 and week 52
</timeframe>
<title>
  Change in Glycosylated Hemoglobin (HbA1c)
</title>
<unitofmeasure>
  percent
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  0.5522
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  36
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  33
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent to treat population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.25
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -1.53
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.27
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -3.10
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Change in fasting plasma glucose from week 0 to week 52 (i.e., fasting plasma glucose at week 52 minus fasting plasma glucose at week 0).
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  0 weeks and 52 weeks
</timeframe>
<title>
  Change in Fasting Plasma Glucose
</title>
<unitofmeasure>
  mmol/L
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  &lt;0.0001
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  36
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  33
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent to treat population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1.80
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.92
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1.91
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.38
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pre-breakfast measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1.63
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7.27
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.85
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  5.63
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pre-breakfast measurement (week 52)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.58
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  11.00
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  3.30
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  11.17
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  2-hour post-breakfast measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.42
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6.98
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.16
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7.53
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  2-hour post-breakfast measurement (week 52)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.25
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.14
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.51
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.54
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pre-lunch measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1.52
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6.52
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1.66
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6.24
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pre-lunch measurement (week 52)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.54
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  9.90
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.96
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10.52
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  2-hour post-lunch measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.01
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7.97
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  1.77
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.15
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  2-hour post-lunch measurement (week 52)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.40
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.38
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.48
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.07
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pre-dinner measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.63
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7.53
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.04
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6.98
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pre-dinner measurement (week 52)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.42
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10.42
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.82
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10.26
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  2-hour post-dinner measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.25
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  6.98
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.03
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.81
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  2-hour post-dinner measurement (week 52)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.44
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  9.76
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  3.09
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  9.85
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Bedtime measurement (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.11
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  7.61
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  2.82
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.03
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Bedtime measurement (week 52)
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  SMBG measured at 7 time points (before and after breakfast, before and after lunch, before and after dinner, at bedtime).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  0 weeks and 52 weeks
</timeframe>
<title>
  Seven Point Self Monitored Blood Glucose (SMBG) Measurements
</title>
<unitofmeasure>
  mmol/L
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  36
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  33
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent to treat population.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.87
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  -3.80
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.95
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  0.75
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Change in body weight from week 0 to week 52 (i.e., body weight at week 52 minus body weight at week 0).
</textblock>
</measuredescription>
<parametertype>
  Least Squares Mean
</parametertype>
<timeframe>
  0 weeks and 52 weeks
</timeframe>
<title>
  Change in Body Weight
</title>
<unitofmeasure>
  kg
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
</othertypename>
<parametertype>
</parametertype>
<parametervalue>
</parametervalue>
<pvalue>
  &lt;0.0001
</pvalue>
<pvaluecomment>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.9-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  36
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.9-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  33
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent to treat population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Error
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.39
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2.24
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.26
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2.79
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  baseline (week -2)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.42
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  3.18
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.32
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  3.85
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.44
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  3.19
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.10-OutcomeRptGroup.2
</reportinggroupid>
<dispersionlowerlimit>
</dispersionlowerlimit>
<dispersionspread>
  0.29
</dispersionspread>
<dispersionupperlimit>
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  2.81
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  week 56
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  M-value at baseline (week -2), week 52 (end of on-drug period), and week 56 (during off-drug period).  Insulin sensitivity was assessed during the euglycemic/hyperglycemic clamp test at baseline (week -2), week 52, and week 56.  Insulin-mediated glucose uptake (M-value) was calculated as the mean glucose requirement during the 90-120 minute interval of the clamp.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  baseline (week -2), 52 weeks, and 56 weeks
</timeframe>
<title>
  M-value at Baseline, Week 52 and Week 56
</title>
<unitofmeasure>
  mg/min/kg
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.10-OutcomeRptGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Exenatide Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.10-OutcomeRptGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Insulin Glargine Arm
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Evaluable population.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<title>
  Exenatide Arm
</title>
</flowgroup>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<title>
  Insulin Glargine Arm
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
<textblock>
  Subjects experiencing loss of glucose control after Week 52 are considered to have completed study.
</textblock>
</comment>
<subjectsachieve>
  30
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
<textblock>
  Subjects experiencing loss of glucose control after Week 52 are considered to have completed study.
</textblock>
</comment>
<subjectsachieve>
  30
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Withdrawal of consent
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  5
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Adverse Event
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Physician Decision
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Lost to Follow-up
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  6
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  3
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  36
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  33
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  On-drug Period (Week 0 to Week 52)
</title>
</period>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  25
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  26
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Withdrawal of consent
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Physician Decision
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  3
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Loss of glucose control
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  5
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  4
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
<textblock>
  Exenatide is discontinued, metformin is continued
</textblock>
</comment>
<subjectsachieve>
  30
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
<textblock>
  Insulin Glargine is discontinued, metformin is continued
</textblock>
</comment>
<subjectsachieve>
  30
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Off-drug Period (Week 52 to Week 64)
</title>
</period>
</periods>
<preassignmentdescription>
</preassignmentdescription>
<recruitmentdetails>
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
  Clinical.Trials@bms.com
</email>
<organizationname>
  Bristol-Myers Squibb
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
</phonenumber>
<title>
  Bristol-Myers Squibb Study Director
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<frequencyreportingthreshold>
  5
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Anemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Abdominal Distension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Diarrhea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Dyspepsia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Flatulence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  18
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Nausea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Injection Site Rash
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Edema Peripheral
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Gastroenteritis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Influenza
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Laryngitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Tooth Infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Urinary Tract Infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Decreased Appetite
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Hyperlipidemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Hypoglycemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Arthralgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Headache
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Proteinuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Hypertension
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  5 mcg twice a day for 4 weeks, followed by 10 mcg twice a day for 8 weeks.  After 12 weeks, exenatide is titrated (up to a maximum of 20 mcg three times a day) based on periodic glycosylated hemoglobin (HbA1c) measurements and tolerability.
</textblock>
</description>
<numsubjectsfrequentevents>
  32
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  3
</numsubjectsseriousevents>
<partatriskfrequentevents>
  36
</partatriskfrequentevents>
<partatriskseriousevents>
  36
</partatriskseriousevents>
<title>
  Exenatide Arm
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.2"
>
<description>
<textblock>
  Dosing starts at 10 IU/day, and is then titrated, based on daily fasting blood glucose measurements.
</textblock>
</description>
<numsubjectsfrequentevents>
  31
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  1
</numsubjectsseriousevents>
<partatriskfrequentevents>
  33
</partatriskfrequentevents>
<partatriskseriousevents>
  33
</partatriskseriousevents>
<title>
  Insulin Glargine Arm
</title>
</interventiongroup>
</interventiongroups>
<notes>
</notes>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Coronary Artery Stenosis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Pancreatitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Diverticulitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  36
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  33
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Non-systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<term>
  Thrombophlebitis Superficial
</term>
</seriousevent>
</seriousadverseevents>
<sourcevocabulary>
  MedDRA 6.1
</sourcevocabulary>
<timeframe>
  Total reporting period for adverse events is 64 weeks: a 52-week on-drug period followed by a 12-week off-drug period.
</timeframe>
</reportedevents>
</clinical_result>
</clinical_study>
